Ligandrol

Muscle Growth & Body Composition

Also known as: LGD-4033, VK-5211, Ligandrol LGD

Selective Androgen Receptor ModulatorsResearch phase: Phase 2Regulatory: Not FDA-approved. WADA prohibited. Under clinical development by Viking Therapeutics. Available as research chemical.

Mechanism

Ligandrol is one of the most potent SARMs, showing significant lean muscle gains even at low doses (1 mg/day). It has completed Phase 2 trials for hip fracture recovery and muscle wasting. It has a high anabolic-to-androgenic ratio but does suppress natural testosterone at higher doses, requiring consideration of post-cycle recovery.

Technical detail

Ligandrol (LGD-4033/VK-5211) is a non-steroidal SARM with high AR binding affinity (Ki ~1 nM) and exceptional anabolic potency. Phase 1 data demonstrated dose-dependent increases in lean body mass (up to 1.21 kg at 1.0 mg/day over 21 days) with concurrent reductions in body fat. It exhibits dose-dependent suppression of total testosterone, SHBG, and FSH/LH without significant effects on PSA or hematocrit. Phase 2 trials (Viking Therapeutics) for hip fracture recovery showed improved lean mass and functional measures.

Build a personalized protocol with Ligandrol →